SANTA ROSA, Calif., Oct. 4 /PRNewswire/ -- Osseon Therapeutics, Inc., a biomedical device company based in Santa Rosa, California, received its second patent Notice of Allowance (NOA) for its spinal vertebral compression fracture (VCF) technology. The company, which was started in 2006, now has two allowed and twelve additional patent applications pending in the United States, and several others throughout the world for spinal therapies and devices.
The company has been marketing its FDA and CE Mark cleared "Osseoplasty™" system in the U.S. and Europe, since February, 2009 and February, 2010, respectively. The proprietary Osseoplasty™ procedure has been performed in over 1,100 patients in the U.S. and Europe.
According to John Stalcup, Ph.D., President and CEO of Osseon, "This second patent allowance for Osseon's spinal VCF technology is another cornerstone for the company's intellectual property foundation. We continue to strengthen our intellectual property position and strive to obtain additional patents in the future on various aspects of the Osseoflex® steerable and curvable needle and the novel methods for bone cement delivery, which enable a safe, effective, and minimally invasive approach for spine disease treatment."
ABOUT Osseon Therapeutics, Inc.
Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the thoracic and lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that tre
|SOURCE Osseon Therapeutics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved